Octreotide, Sutent and Nexovar…
- This topic has 5 replies, 4 voices, and was last updated 13 years ago by
.
-
Posts
-
Patti I just wanted to say thanks for posting this info. I made a copy of the papers on octreotide and gave them to my Dr last month. He did some more checking and is ordering a blood test my next visit to evaluate if it may be effective. WooHoo anything that may help is greatly appreciated, especially when it is a non- chemo drug with little side effects. Options are so limited, so it is nice when something new is found. Dr was not aware it was being used for CC so it was great information! This board is so great for so many reasons, including sharing what may be helping. Thanks again and God Bless,
JamieYes, I ran everything. I have Malware, Defraggler and a cleaner also re booted and it seems to be better now. Thanks Gavin.
P.S. The picture was up in left hand corner, where the original Cancer picture was. But all seems ok now.Have you ran an antivirus/spyware scan or scans since that flashing picture appeared Lainy? And is the picture on your desktop or coming out of the bottom bar on your screen?
Hi folks,
The Cancernetwork site above did not cause me any issues…However, I would recommend that you follow Lainy’s advice.
Not sure what the issue is, but would exercise caution, as Lainy mentioned. The information that was on this page is as follows:
Cholangiocarcinoma: Rare, refractory, and rising
July 20, 2010
FEATURED SEARCH: cholangiocarcinoma
The increasing incidence of the liver malignancy cholangiocarcinoma is troubling, especially because it’s difficult to detect and treatments have a high failure rate. But oncology is making inroads against it, according to reports from the field. In the review below, authors from Texas A&M point out tremendous progress in finding molecular strategies to control the growth of this rare cancer. There’s also cause for cautious cheer on the clinical front: the kinase inhibitor sorafenib is showing promising results, food-based polyphenols are in testing as adjuvants to boost the effects of chemotherapy, and results of neoadjuvant treatment followed by liver transplant have been encouraging. In the second article, Italian surgeons have verified that responding aggressively to recurrences of intrahepatic cholangiocarcoma (IHCC) is worth the effort.
RESULT: Recent advances in the regulation of cholangiocarcinoma growth
American Journal of PhysiologyBe very careful if you open this link from the post above!!!!!!!!!!!!!!!!!
I now have a flashing picture about Cancer that I cannot get off my screen no matter what site I go in to!!!!!!!
http://www.cancernetwork.com/gastrointestinal-strom
My brother Bruce is currently taking Octreotide (monthly injections) with what appears to be some success. Here is some information on Octreotide. The first two articles offer some hopeful conclusions and the third article provides a good summary of what Octreotide is and what it does:
http://www.ncbi.nlm.nih.gov/pubmed/12483273
http://www.ncbi.nlm.nih.gov/pubmed/7768398
http://www.chemocare.com/bio/octreotide.asp
When testing Bruce’s tissue sample at the lab in AZ (http://www.targetnow.com), Sutent and Nexovar (in addition to Octreotide) were identified as working well against Bruce’s tumor.
Information regarding Sutent:
This is one of the “targeted agents” that Dr. Marks indicated was identified as working with Bruce’s cancer (from lab work done in AZ on Bruce’s tissue).
http://www.vancouversun.com/mobile/iphone/story.html?id=4678729Information regarding Nexovar:
Nexovar is the trade name for sorafenib. It
- The forum ‘New Developments’ is closed to new topics and replies.